semaglutide sglt2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application SGLT2 Inhibitors and GLP-1 Receptor

Description

Between 2026 and 2027, several new medications are expected to reach the marketincluding oral GLP-1 drugs, dual-hormone therapies, and even triple-hormone agents designed to target multiple metabolic pathways at onc

Live in Illinois

Semaglutide (sold under the brand names Waygovy or Ozempic) is an FDA-approved weight loss medication that falls under the category of GLP-1 receptor agonists

Objective This systematic review aims to synthesise published evidence on respiratory adverse events temporally associated with GLP-1 RA therapy in adults, characterise their patterns and severity, appraise the risk of bias using validated design-appropriate tools, describe proposed pathophysiological mechanisms, and grade the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework